Caribou Biosciences shares are trading lower after the company presented clinical data from the CB-010 ANTLER Phase 1 trial in second-line LBCL patients at the 2024 ASCO Annual Meeting.
Portfolio Pulse from Benzinga Newsdesk
Caribou Biosciences shares are trading lower after presenting clinical data from the CB-010 ANTLER Phase 1 trial in second-line LBCL patients at the 2024 ASCO Annual Meeting.
June 03, 2024 | 5:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Caribou Biosciences shares are trading lower following the presentation of clinical data from the CB-010 ANTLER Phase 1 trial in second-line LBCL patients at the 2024 ASCO Annual Meeting.
The decline in Caribou Biosciences' share price is directly linked to the market's reaction to the clinical data presented at the ASCO Annual Meeting. Investors may have found the data less promising than expected, leading to a sell-off.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100